By Counterforce Health Team in Ilaris (canakinumab) —

How to Get Ilaris (Canakinumab) Covered by Cigna in Washington: Complete Prior Authorization and Appeal Guide

Answer Box: Fast Track to Ilaris Approval

Getting Ilaris (canakinumab) covered by Cigna in Washington requires prior authorization with specific clinical documentation. Your fastest path: (1) Ensure you meet Cigna's diagnosis criteria for Still's disease, periodic fever syndromes, or gout flares with elevated CRP ≥10 mg/L, (2) Document failure/intolerance of standard therapies like NSAIDs, corticosteroids, or other biologics, and (3) Submit through a board-certified specialist using Cigna's Policy IP0235. If denied, Washington's external review process through an Independent Review Organization (IRO) offers strong patient protections with binding decisions.

Table of Contents

  1. Cigna's Coverage Policy Overview
  2. Medical Necessity Requirements
  3. Step Therapy & Exception Pathways
  4. Quantity Limits & Dosing Requirements
  5. Required Diagnostics & Documentation
  6. Specialty Pharmacy & Site of Care
  7. Clinical Evidence Guidelines
  8. Appeals Process in Washington
  9. Common Denial Reasons & Solutions
  10. Cost Savings & Patient Support
  11. FAQ

Cigna's Coverage Policy Overview

Cigna covers Ilaris (canakinumab) under their specialty pharmacy benefit, typically managed through Express Scripts/Accredo. The medication requires prior authorization across all plan types—HMO, PPO, and Medicare Advantage—with coverage determined by their Policy IP0235.

Plan Types and Coverage:

  • Commercial plans: Full PA requirements apply
  • Medicare Advantage: Additional CMS guidelines may apply
  • Medicaid managed care: Subject to state Medicaid policies plus Cigna requirements

All submissions must reference Policy IP0235 and include comprehensive clinical documentation to avoid automatic denials.

Medical Necessity Requirements

Cigna requires specific clinical criteria for each approved indication:

Still's Disease (AOSD/SJIA)

  • Documented diagnosis with appropriate ICD-10 codes (M04.10 for SJIA)
  • Elevated C-reactive protein (CRP) ≥10 mg/L or ≥2x upper limit of normal
  • Prescription by or consultation with board-certified rheumatologist, geneticist, nephrologist, oncologist, or hematologist
  • History of ≥6 disease flares per year OR hospitalization for severe flare despite standard therapy

Periodic Fever Syndromes (TRAPS, HIDS/MKD, FMF)

  • Genetic confirmation when available
  • Documentation of recurrent fever episodes
  • Failure of standard preventive therapies

Gout Flares

  • Adult patients only
  • Not candidates for or failed standard options (NSAIDs, colchicine, corticosteroids)
  • 150 mg dose with ≥12-week intervals between treatments

Step Therapy & Exception Pathways

Required Prior Therapies:

  1. NSAIDs (document dose, duration, reason for discontinuation)
  2. Corticosteroids (include tapering attempts and outcomes)
  3. Conventional DMARDs like methotrexate (for Still's disease)
  4. Other biologics such as anakinra or tocilizumab (condition-specific)

Medical Exception Documentation:

  • Contraindications to standard therapies
  • Documented intolerance with specific adverse effects
  • Treatment failures with objective measures (lab values, symptom scores)
  • Include dosage, duration, and clinical response for each prior therapy

Quantity Limits & Dosing Requirements

FDA-Approved Dosing by Condition:

Condition Weight Dose Frequency
Still's Disease ≥7.5 kg 4 mg/kg (max 300 mg) Every 4 weeks
Periodic Fever Syndromes >40 kg 150-300 mg Every 4 weeks
Periodic Fever Syndromes ≤40 kg 2-4 mg/kg Every 4 weeks
Gout Flares Adults 150 mg Single dose (≥12 weeks apart)

Cigna enforces these limits strictly. Requests for higher doses or more frequent administration require additional clinical justification.

Required Diagnostics & Documentation

Laboratory Requirements:

  • Recent CRP levels (≥10 mg/L required for Still's disease)
  • Complete blood count with differential
  • Comprehensive metabolic panel
  • ESR (erythrocyte sedimentation rate)
  • Ferritin levels (often markedly elevated in Still's disease)

Clinical Documentation:

  • Detailed history and physical examination
  • Prior therapy documentation with outcomes
  • Specialist consultation notes
  • Hospital records if applicable for severe flares

Timing: Labs should be within 30 days of submission for acute conditions, within 90 days for chronic management.

Specialty Pharmacy & Site of Care

Cigna requires Ilaris distribution through Accredo Specialty Pharmacy. The medication is administered as a subcutaneous injection by a healthcare provider.

Site of Care Requirements:

  • Home administration by certified nurse (preferred)
  • Outpatient ambulatory infusion center
  • Hospital outpatient setting (requires medical necessity justification)

Cigna follows "least intensive, medically appropriate setting" policies to control costs while ensuring safe administration.

Clinical Evidence Guidelines

Current treatment guidelines support early biologic intervention for Still's disease and periodic fever syndromes:

ACR/EULAR 2024 Recommendations:

  • Early IL-1 inhibitor therapy (including canakinumab) for active systemic features
  • Prompt treatment within the "window of opportunity" for best outcomes
  • Goal of achieving Clinically Inactive Disease (CID)

Medical Necessity Letter Components:

  1. Diagnosis per unified criteria (Yamaguchi for AOSD, ILAR for SJIA)
  2. Evidence of active disease with systemic features
  3. Documentation of inadequate response to conventional therapy
  4. Citation of relevant treatment guidelines
  5. Treatment goals and monitoring plan
From our advocates: We've seen the strongest approvals when providers include specific guideline citations—like the 2024 ACR/EULAR Still's disease recommendations—alongside objective measures of disease activity. One rheumatologist improved their approval rate by consistently referencing Policy IP0235 in their medical necessity letters and including recent CRP values with each submission.

Appeals Process in Washington

Washington State provides robust patient protections for insurance denials through a structured appeals process.

Internal Appeals (Required First Step):

  • File within 180 days of denial notice
  • Cigna must respond within 30 days (15 days for urgent cases)
  • Include all supporting clinical documentation

External Review Process:

  • Available after internal appeal completion
  • File within 4 months of final internal denial
  • Washington Office of the Insurance Commissioner assigns Independent Review Organization (IRO)
  • Decision within 20 days (72 hours for expedited cases)
  • IRO decision is binding on Cigna

Key Advantage: Washington's external reviewers can override Cigna's medical necessity standards if found "unreasonable or inconsistent with sound, evidence-based medical practice."

Common Denial Reasons & Solutions

Denial Reason Solution Strategy
Insufficient prior therapy documentation Provide detailed records of each medication trial with doses, duration, and specific reasons for discontinuation
CRP not meeting threshold Obtain recent lab work showing CRP ≥10 mg/L; if normal, document other inflammatory markers
Non-specialist prescriber Obtain rheumatologist consultation or co-signature
Diagnosis criteria not met Include specific diagnostic criteria documentation (Yamaguchi, ILAR) with supporting clinical findings
Quantity/frequency exceeded Justify based on FDA labeling and clinical response; consider dose optimization documentation

Cost Savings & Patient Support

Manufacturer Support:

Additional Resources:

  • Patient advocate organizations for rare disease support
  • Washington State pharmaceutical assistance programs
  • Counterforce Health provides specialized appeal assistance for complex prior authorization denials, helping patients and providers turn insurance rejections into targeted, evidence-backed appeals

FAQ

How long does Cigna prior authorization take in Washington? Standard PA decisions: 15 business days. Urgent requests: 72 hours. Incomplete submissions may face additional delays.

What if Ilaris is non-formulary on my plan? Request formulary exception with medical necessity documentation. Emphasize lack of therapeutic alternatives and clinical guidelines supporting use.

Can I get expedited review for urgent cases? Yes, if delay would seriously jeopardize your health. Both internal appeals and external review offer expedited pathways in Washington.

Does step therapy apply if I tried medications outside Washington? Yes, out-of-state prior therapy records are acceptable. Ensure complete documentation including prescriber notes and outcomes.

What happens if the external review upholds the denial? The decision is final for the insurance appeal process. Consider contacting the Washington Insurance Commissioner at 1-800-562-6900 for additional guidance.

How much does Ilaris cost without insurance? Cash prices typically range $20,000-$23,000 per 150mg syringe. Patient assistance programs may significantly reduce costs for eligible individuals.

When to Escalate

Contact the Washington Office of the Insurance Commissioner if:

  • Cigna fails to meet required timelines
  • You believe the denial violates Washington insurance law
  • The external review process isn't properly followed

Contact Information:

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage policies change frequently. Always verify current requirements with Cigna and consult your healthcare provider for medical decisions. For personalized assistance with complex denials, Counterforce Health specializes in transforming insurance rejections into successful appeals through targeted clinical documentation and evidence-based advocacy.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.